Guaifenesin 1200 Mg Tablet, Extended Release
NDC Package 43598-009-10
Package Information
Guaifenesin 1200 Mg (guaifenesin) tablets is a medication used for the temporary relief of coughs caused by the common cold, bronchitis, and other breathing illnesses. This formulation utilizes a tablet, extended release delivery system. Marketed by Dr. Reddy's Laboratories Inc., this product is identified by NDC 43598-009 and is authorized under FDA application ANDA215932.
Identification & Billing
- RxCUI: 310621 - guaiFENesin 1200 MG 12HR Extended Release Oral Tablet
- RxCUI: 310621 - 12 HR guaifenesin 1200 MG Extended Release Oral Tablet
- RxCUI: 310621 - guaifenesin 1200 MG 12 HR Extended Release Oral Tablet
- RxCUI: 636522 - guaiFENesin 600 MG 12HR Extended Release Oral Tablet
- RxCUI: 636522 - 12 HR guaifenesin 600 MG Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 43598 - Dr. Reddy's Laboratories Inc.
- 43598-009 - Guaifenesin 1200 Mg
- 43598-009-10 - 1000 TABLET, EXTENDED RELEASE in 1 POUCH
- 43598-009 - Guaifenesin 1200 Mg
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (43598-009). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 43598-009-10 identifies a specific commercial package of 1000 tablet, extended release in 1 pouch of Guaifenesin 1200 Mg, a human over the counter drug labeled by Dr. Reddy's Laboratories Inc.. This tablet, extended release is formulated for oral use and contains guaifenesin as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Dr. Reddy's Laboratories Inc. on March 15, 2022. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used for the temporary relief of coughs caused by the common cold, bronchitis, and other breathing illnesses. This product is usually not used for ongoing cough from smoking or long-term breathing problems (such as chronic bronchitis, emphysema) unless directed by your doctor. Guaifenesin is an expectorant. It works by thinning and loosening mucus in the airways, clearing congestion, and making breathing easier. If you are self-treating with this medication, it is important to read the package instructions carefully before you start using this product to be sure it is right for you. (See also Precautions section.) Cough-and-cold products have not been shown to be safe or effective in children younger than 6 years. This product (sustained-release) is not recommended for use in children younger than 12 years unless specifically directed by the doctor. Ask your doctor or pharmacist for more details about using your product safely. These products do not cure or shorten the length of the common cold. To decrease the risk for side effects, carefully follow all dosage directions. Do not give other cough-and-cold medication that might contain the same or similar ingredients (see also Drug Interactions section). Ask the doctor or pharmacist about other ways to relieve cough and cold symptoms (such as drinking enough fluids, using a humidifier or saline nose drops/spray).
How is this Dr. Reddy's Laboratories Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 43598000910. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.